Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.


Clinical Trial Description

The maximum tolerated dose of TB-403 will be determined in pediatric subjects with relapsed or refractory Medulloblastoma (MB) and as well Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02748135
Study type Interventional
Source Oncurious NV
Contact
Status Completed
Phase Phase 1
Start date May 2016
Completion date October 6, 2020